Biodesix shares ended the last trading session 10.5% higher at $16.81 on heavy volume. The jump followed Canaccord Genuity raising its price target on the company from $22.00 to $27.00 while maintaining a Buy rating. Biodesix reported strong progress in the first quarter of 2026 across its three objectives of driving top-line growth, improving operational efficiency and leverage, and advancing its pipeline. The company is expected to post a quarterly loss of $0.85 per share, a 46.9% improvement year-over-year, on revenues of $26.1 million, up 30.4% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 4% higher over the last 30 days, and the stock carries a Zacks Rank of 2, or Buy.
Biodesix IncCanaccord Genuity raised price target to $27 and maintained Buy rating, citing strong Q1 progress and improving financials.
Goodrx Holdings Inc